



- (51) **International Patent Classification:**
C07D 487/04 (2006.01) *A61K 31/519* (2006.01)
- (21) **International Application Number:**
PCT/US2015/067831
- (22) **International Filing Date:**
29 December 2015 (29.12.2015)
- (25) **Filing Language:** English
- (26) **Publication Language:** English
- (30) **Priority Data:**
62/098,141 30 December 2014 (30.12.2014) US
- (71) **Applicant: FORMA THERAPEUTICS, INC.** [US/US];
500 Arsenal Street, Suite 100, Watertown, Massachusetts
02472 (US).
- (72) **Inventors: IOANNIDIS, Stephanos**; 8 Penobscot Road,
Natick, Massachusetts 01760 (US). **TALBOT, Adam
Charles**; 3 Hart Landing, Guilford, Connecticut 06437
(US). **FOLLOWS, Bruce**; 25 Baldwin Hill Rd, Littleton,
Massachusetts 01460 (US). **BUCKMELTER, Alexandre
Joseph**; 139 Prospect Street #5, Acton, Massachusetts
01720 (US). **WANG, Minghua**; 30 Squirrel Hill, Acton,
Massachusetts 01720 (US). **CAMPBELL, Ann-Marie**;
248 Webb Circle, Monroe, Connecticut 06468 (US).
SCHMIDT, Darby Rye; 14 Mead Road, Arlington, Mas-
sachusetts 02474 (US). **GUERIN, David Joseph**; 16 Hunt-
ington Street, Natick, Massachusetts 01760 (US). **CARA-
VELLA, Justin A.**; 121 Sciarappa St. #3, Cambridge,
Massachusetts 02141 (US). **DIEBOLD, R. Bruce**; 2
Dolores Ave. Apt. 11, Waltham, Massachusetts 02452

(US). **ERICSSON, Anna**; 16 Venus Drive, Shrewsbury,
Massachusetts 01545 (US). **LANCIA, JR., David**; 45 W
Broadway, Unit 111, Boston, Massachusetts 02127 (US).

(74) **Agents: FARMER, Dean** et al.; Cooley LLP, 1299
Pennsylvania Avenue, Suite 700, Washington, District of
Columbia 20004 (US).


(81) **Designated States** (*unless otherwise indicated, for every
kind of national protection available*): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY,
BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM,
DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,
HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR,
KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG,
MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM,
PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC,
SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN,
TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) **Designated States** (*unless otherwise indicated, for every
kind of regional protection available*): ARIPO (BW, GH,
GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ,
TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU,
TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE,
DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU,
LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK,
SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ,
GW, KM, ML, MR, NE, SN, TD, TG).

Published:

— with international search report (Art. 21(3))

(54) **Title:** PYRROLO AND PYRAZOLOPYRIMIDINES AS UBIQUITIN-SPECIFIC PROTEASE 7 INHIBITORS



(I)

(57) **Abstract:** The invention relates to inhibitors of USP7 inhibitors useful in the treatment of cancers, neurodegenerative diseases, immunological disorders, inflammatory disorders, cardiovascular diseases, ischemic diseases, viral infections and diseases, and bacterial infections and diseases, having the Formula: (I) where m, n, X₁, X₂, R₁-R₅, R₅ and R₆ are described herein.